Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. INBX
stocks logo

INBX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-2.080
-53.47%
--
--
-1.210
-56.79%
--
--
-1.120
-39.46%
Estimates Revision
The market is revising No Change the revenue expectations for Inhibrx, Inc. (INBX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 210.18%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+210.18%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Inhibrx Biosciences Inc (INBX.O) is -15.58, compared to its 5-year average forward P/E of -2.21. For a more detailed relative valuation and DCF analysis to assess Inhibrx Biosciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.21
Current PE
-15.58
Overvalued PE
1.50
Undervalued PE
-5.91

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
5.56
Current PS
0.00
Overvalued PS
43.35
Undervalued PS
-32.24
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

INBX News & Events

Events Timeline

(ET)
2025-11-05
08:45:01
Significant Borrowing Rate Hikes Among Liquid Assets
select
2025-10-23 (ET)
2025-10-23
16:19:56
Inhibrx announces favorable topline outcomes from ozekibart registration trial
select
2025-08-13 (ET)
2025-08-13
16:07:30
Inhibrx reports Q2 EPS ($1.85) vs. $125.48 last year
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.0
11-21SeekingAlpha
Top Quant-Rated Small and Mid-Cap Healthcare Stocks as LLY Reaches $1 Trillion Market Capitalization

  • Eli Lilly's Milestone: Eli Lilly becomes the first pharmaceutical company to reach a $1 trillion market cap, highlighting significant growth in the healthcare sector.

  • Quant-Rated Stocks: Seeking Alpha identifies several mid-to-small-cap healthcare stocks rated as "Strong Buy" by its Quant rating system, all under $7 billion in market cap.

  • Performance of Quant Model: The Seeking Alpha Quant Model has shown exceptional performance, with its stock recommendations outperforming the S&P 500 by 1,755% from January 2010 to June 2021.

  • Top Rated Stocks: Featured stocks include Inhibrx Biosciences, Nektar Therapeutics, and GRAIL, Inc., all showing substantial year-to-date gains and strong buy ratings.

[object Object]
Preview
9.0
11-17NASDAQ.COM
INBX Progresses Ozekibart Initiative, Aims for BLA Submission for Chondrosarcoma by Q2 2026

  • Financial Results: Inhibrx Biosciences reported a net loss of $35.3 million for Q3 2025, an improvement from a $43.9 million loss in the same quarter the previous year, with cash reserves of $153.1 million as of September 30, 2025.

  • Ozekibart Development: The company plans to submit a Biologics License Application (BLA) for its lead drug candidate, Ozekibart, in chondrosarcoma by Q2 2026, following positive Phase 3 trial results showing significant improvements in progression-free survival.

  • Clinical Trials: Ozekibart is also undergoing Phase I trials for advanced solid tumors, with promising interim data for colorectal cancer and Ewing sarcoma patients. Additionally, Inhibrx is advancing INBRX-106, an immune agonist, in various clinical studies.

  • Stock Performance: Inhibrx's stock has fluctuated between $10.81 and $86.64 over the past year, closing at $79.13 on November 14, 2025, reflecting a 6.04% increase.

[object Object]
Preview
9.5
11-14PRnewswire
Inhibrx Reports Third Quarter 2025 Financial Results

  • Financial Results: Inhibrx reported a net loss of $35.3 million for Q3 2025, an improvement from a $43.9 million loss in Q3 2024, with cash and cash equivalents totaling $153.1 million as of September 30, 2025.

  • Clinical Trial Updates: The company announced positive topline results for ozekibart (INBRX-109) in chondrosarcoma, meeting its primary endpoint and showing significant improvements in patient outcomes, with plans to submit a biologics license application to the FDA in Q2 2026.

  • Research and Development Expenses: R&D expenses decreased to $28.5 million in Q3 2025 from $38.9 million in Q3 2024, attributed to reduced process development activities and a decrease in personnel-related costs.

  • Corporate Structure: Inhibrx was established as a subsidiary of Inhibrx, Inc. following the sale of INBRX-101 to Sanofi S.A. and has a clinical pipeline that includes ozekibart and INBRX-106, focusing on innovative protein engineering methods.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Inhibrx Biosciences Inc (INBX) stock price today?

The current price of INBX is 87.41 USD — it has increased 5.36 % in the last trading day.

arrow icon

What is Inhibrx Biosciences Inc (INBX)'s business?

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Its clinical pipeline of therapeutic candidates includes ozekibart (INBRX-109) and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that it designed with its proprietary single domain antibody (sdAb) platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist which is being investigated as a single agent and in combination with KEYTRUDA (pembrolizumab), a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors.

arrow icon

What is the price predicton of INBX Stock?

Wall Street analysts forecast INBX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for INBX is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Inhibrx Biosciences Inc (INBX)'s revenue for the last quarter?

Inhibrx Biosciences Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Inhibrx Biosciences Inc (INBX)'s earnings per share (EPS) for the last quarter?

Inhibrx Biosciences Inc. EPS for the last quarter amounts to -2.28 USD, decreased -19.72 % YoY.

arrow icon

What changes have occurred in the market's expectations for Inhibrx Biosciences Inc (INBX)'s fundamentals?

The market is revising No Change the revenue expectations for Inhibrx, Inc. (INBX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 210.18%.
arrow icon

How many employees does Inhibrx Biosciences Inc (INBX). have?

Inhibrx Biosciences Inc (INBX) has 156 emplpoyees as of December 05 2025.

arrow icon

What is Inhibrx Biosciences Inc (INBX) market cap?

Today INBX has the market capitalization of 1.27B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free